Loading…
Fierce Drug Dev Forum 2019 has ended
avatar for Rich Daly

Rich Daly

BEYONDSPRING PHARMACEUTICALS
Chief Operating Officer
Over the last 20 years Rich Daly has targeted his efforts on developing strategies and execution plans in two challenging areas: transforming R&D focused organizations into integrated R&D AND Commercial companies; and reinvigorating struggling commercial teams.

Mr. Daly currently serves as the COO for BeyondSpring Inc. (NASDAQ: BYSI), a global, clinical-stage biotech company with multiple late phase 3 programs in oncology and early stage clinical programs in protein degradation.

His leadership portfolio includes executive roles as the CEO of a publicly traded small cap biotech; President of the U.S. division ($1.5 billion, 2,500 employees) of an international large pharma; EVP of North and South America responsible for geographic expansion of a top 15 pharma; and 10 product launches.
Additionally, he has served on four public company boards and currently serves on the boards of two NASDAQ companies.

Mr. Daly received his bachelor of science degree in microbiology from the University of Notre Dame and his MBA from the Kellogg Graduate School of Management, Northwestern University.